Sangamo Therapeutics, Inc.
NASDAQ:SGMOBiotechnology
Healthcare
$0.18 +2.06%
+$0.00 today
- Market cap
- $70.43M
- Beta
- 1.29
- P/E (TTM)
- -0.5
- EPS (TTM)
- -$0.32
52W Low $0.10High $0.77
Volume 0.61M
Average 9.53M
Balance Sheet
Inspect the capital base behind the business.
Assets
$59.74M
FY 2025 · Annual
-41.2% YoYLiabilities
$74.01M
FY 2025 · Annual
-6.2% YoYEquity
-$14.27M
FY 2025 · Annual
Balance Sheet
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 178.87M | 100.44M | 45.2M | 41.92M | 20.95M |
| Short-term Investments | 197.68M | 177.19M | 35.8M | 0 | 0 |
| Net Receivables | 6.36M | 4.47M | 4.07M | 4.6M | 10.51M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 9.26M | 5.18M | 4.37M |
| Total Current Assets | 398.77M | 300.33M | 94.33M | 51.69M | 35.83M |
| Property, Plant & Equipment (Net) | 124.7M | 125.53M | 52.87M | 34.76M | 14.11M |
| Goodwill | 39.7M | 37.55M | 0 | 0 | 0 |
| Intangible Assets | 53.76M | 50.73M | 0 | 0 | 0 |
| Long-term Investments | 88.17M | 29.85M | 1.5M | 1.5M | 0 |
| Tax Assets | 0 | 6.27M | 0 | 0 | 0 |
| Other Non-current Assets | 16.82M | 12.25M | 16.63M | 13.69M | 9.81M |
| Total Non-current Assets | 323.15M | 262.18M | 70.99M | 49.94M | 23.92M |
| Total Assets | 721.92M | 562.51M | 165.32M | 101.64M | 59.75M |
| Account Payables | 9.76M | 22.42M | 15.26M | 15.49M | 14.44M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 4.07M | 10.14M |
| Deferred Revenue | 85.71M | 51.78M | 0 | 7.56M | 899K |
| Other Current Liabilities | 20.84M | 11.89M | 11.73M | 14.57M | 17.72M |
| Total Current Liabilities | 127.89M | 111.71M | 47.73M | 45.81M | 42.47M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 6.65M | 6.27M | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 166.78M | 109.38M | 0 | 5.87M | 5.87M |
| Other Non-current Liabilities | 1.22M | 1.21M | 1.19M | 933K | 580K |
| Total Non-current Liabilities | 218.69M | 155.84M | 34.7M | 33.06M | 31.55M |
| Total Liabilities | 346.58M | 267.55M | 82.43M | 78.87M | 74.01M |
| Common Stock | 1.46M | 1.67M | 1.78M | 2.13M | 3.51M |
| Retained Earnings | (956.27M) | (1.15B) | (1.41B) | (1.5B) | (1.63B) |
| Accumulated OCI | (3.99M) | (8.4M) | (4.6M) | (7.53M) | (1.46M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 375.34M | 294.96M | 82.89M | 22.77M | (14.27M) |
| Total Debt | 48.08M | 43.11M | 38.1M | 30.57M | 26.8M |
| Net Debt | (130.79M) | (57.34M) | (7.1M) | (11.35M) | 5.85M |
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $27.6M |
| Receivables | $6.4M |
| Other Current | $3.2M |
| Total Current Assets | $37.1M |
| PP&E (Net) | $13.2M |
| Other Non-current | $9.6M |
| Total Non-current Assets | $22.9M |
| Total Assets | $60.0M |
Analysis
Selected assets total $60.0M for Latest. The largest visible component is Cash & Equivalents at $27.6M, about 46.0% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | May 27, 2026 | |
| 4 | Statement of changes in beneficial ownership | May 27, 2026 | |
| 4 | Statement of changes in beneficial ownership | May 27, 2026 | |
| 4 | Statement of changes in beneficial ownership | May 27, 2026 | |
| 4 | Statement of changes in beneficial ownership | May 27, 2026 |
How much cash does SGMO have?
Sangamo Therapeutics, Inc. (SGMO) reported $20.95M in cash and equivalents in fiscal 2025.
How much debt does SGMO carry?
Sangamo Therapeutics, Inc. (SGMO) reported $26.80M of total debt, with net debt of $5.85M.
Continue the stock analysis
Jump to another research area for this company.